Snoop, spray 45 mcg/dose 15 ml

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes narrowing of blood vessels of nasal mucosa, eliminating edema and hyperemia of nasal mucosa, restores nasal passageway, facilitates nasal breathing.

The action of the drug starts 5-10 minutes after application and lasts up to 12 hours.

Indications

acute respiratory diseases with symptoms of rhinitis (runny nose);
acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa);
to facilitate rhinoscopy and other diagnostic procedures in the nasal passages.

Pharmacological effect

Pharmacotherapeutic group

Anticongestant – alpha-adrenergic agonist.

Pharmacodynamics

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes constriction of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasal mucosa, restores the patency of the nasal passages, and facilitates nasal breathing.

The effect of the drug occurs 5-10 minutes after its use and lasts up to 12 hours.

Pharmacokinetics

When applied topically, the drug is practically not absorbed, so its concentration in the blood plasma is very low (not determined by modern analytical methods).

Special instructions

Sea water, which is part of the drug, helps maintain the normal physiological state of the nasal mucosa due to its ability to improve the function of the ciliated epithelium and normalize the production of mucus in the goblet cells of the mucous membrane.

It is not recommended to use continuously for more than 7 days.

Do not exceed recommended doses, especially in children and the elderly.

Long-term (more than 7 days) use or overdose of xylometazoline can weaken the therapeutic effect of the drug and also increases the risk of reactive hyperemia and atrophy of the nasal mucosa.

Effect on the ability to drive vehicles and operate machinery: if the dosage regimen is followed, xylometazoline does not affect concentration and the speed of psychomotor reactions.

Active ingredient

Xylometazoline

Composition

1 ml nasal spray contains:

Active ingredient:

Xylometazoline hydrochloride 0.45 mcg.

Excipients: Sea water, Potassium dihydrogen phosphate, Purified water.

Pregnancy

During pregnancy, the use of the drug is contraindicated.

During breastfeeding, the drug should be used only after a thorough assessment of the risk-benefit ratio for the mother and child; the recommended dosage should not be exceeded. During breastfeeding, you should consult your doctor before using Snoop®.

Contraindications

Hypersensitivity to xylometazoline or any other component of the drug; arterial hypertension, tachycardia, severe atherosclerosis; increased intraocular pressure, especially angle-closure glaucoma; atrophic rhinitis, hyperthyroidism, surgical interventions on the meninges (history), inflammatory diseases of the skin or mucous membrane of the nasal vestibule, conditions after transsphenoidal hypophysectomy, pregnancy, children under 6 years of age (for nasal spray dosed 90 mcg/dose), children under 2 years of age (for nasal spray dosed 45 mcg/dose).

Do not use during therapy with monoamine oxidase inhibitors (MAOIs) (including 14 days after their discontinuation), tricyclic and tetracyclic antidepressants, other local vasoconstrictors (decongestants), as well as other drugs that increase blood pressure.

With caution

Diabetes mellitus, severe cardiovascular diseases (including coronary heart disease, angina pectoris), prostatic hyperplasia, pheochromocytoma, porphyria, breastfeeding period, with increased sensitivity to adrenergic drugs, accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure; patients with long QT syndrome.

Side Effects

Classification of the frequency of occurrence of adverse reactions: very often (> 1/10); often (> 1/100 to 1/1000 to 1/10,000 to < 1/1000); very rare (< 1/10000).From the immune system:Very rare: hypersensitivity reactions (angioedema, rash, itching).From the nervous system:Common: headache.Rarely: insomnia, depression (with long-term use in high doses).Very rare: restlessness, fatigue, paresthesia, hallucinations and convulsions (mainly in children).From the senses:Very rare: impaired visual clarity.From the cardiovascular system:Rarely: palpitations, increased blood pressure.Very rare: tachycardia, arrhythmia.From the respiratory system:Often: irritation and/or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion of the nasopharyngeal mucosa.Rarely: after using the drug, increased swelling of the nasal mucosa (reactive hyperemia) and nosebleeds may be observed.From the digestive system:Common: nausea.Rarely: vomiting.Local reactions:Common: burning at the application site.If you experience the side effects listed in the instructions or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Concomitant use of xylometazoline with monoamine oxidase inhibitors (MAOIs), tricyclic and tetracyclic antidepressants, other local vasoconstrictors (decongestants), and

Also, other drugs that increase blood pressure can lead to an increase in blood pressure, so the simultaneous use of these drugs is contraindicated.

If you are using the above or other medications (including over-the-counter medications), consult your doctor before using Snoop®.

Overdose

Symptoms:

In case of an overdose of the drug, the clinical picture is an alternation of phases of excitation of the central nervous system (restlessness, agitation, hallucinations, convulsions) with phases of depression of the central nervous system (decreased body temperature, lethargy, drowsiness, coma).

The following symptoms may also occur:

miosis, mydriasis, increased sweating, increased body temperature, pallor, cyanosis, nausea and vomiting, tachycardia, bradycardia, cardiac arrhythmias, cardiac arrest, palpitations, increased blood pressure

pressure, decreased blood pressure up to shock, pulmonary edema, respiratory depression and apnea, psychogenic disorders.

In children with overdose, dominant central effects are observed with convulsions, coma and bradycardia, apnea, as well as increased blood pressure, followed by hypotension.

Treatment:

Symptomatic, under medical supervision.

In case of accidental ingestion of the drug, administration of activated carbon and gastric lavage.

In case of severe overdose, intensive care in a hospital is indicated.

In serious cases, non-selective alpha-blockers to lower blood pressure, antipyretics, intubation and mechanical ventilation may be used.

Prescribing

Anticongestant – alpha adrenergic agonist

Complete set of goods

Nasal spray 0.05%. 15 ml nasal spray (150 doses) in a polyethylene bottle with a spray system.

1 bottle with instructions for medical use of the drug is placed in a cardboard box.

Functional features

When applied topically, the drug is practically not absorbed, so its concentration in the blood plasma is very low (not determined by modern analytical methods).

Storage conditions

At a temperature not higher than 25°C.

After opening the bottle, the drug must be used within 12 months.

Keep out of the reach of children.

Shelf life

5 years.

The contents of the bottle are sterile, without preservatives.

Do not use after expiration date.

If the medicine has expired, do not throw it into wastewater or onto the street!

Place the medication in the trash.

These measures will help protect the environment.

Manufacturer

Hemomont D.O.O, Montenegro